MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

BACKGROUND: Prostate cancer is a common disease in men and at present there is no effective therapy available due to its recurrence despite androgen deprivation therapy. The epidermal growth factor receptor family (EGFR/HER1, HER2/neu and HER3)/PI3K/Akt signaling axis has been implicated in prostate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Qi, Wenqing, Cooke, Larry S, Stejskal, Amy, Riley, Christopher, Croce, Kimiko Della, Saldanha, Jose W, Bearss, David, Mahadevan, Daruka
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2685437/
https://ncbi.nlm.nih.gov/pubmed/19432987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-142
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados